| Title |
Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome
|
|---|---|
| Published in |
Clinical Pharmacokinetics, February 2016
|
| DOI | 10.1007/s40262-015-0363-2 |
| Pubmed ID | |
| Authors |
Stephanie E. Reuter, Jennifer H. Martin |
| Abstract |
Anorexia can affect up to 90 % of people with advanced cancer. It is a complex symptom associated with changes in taste, lack of hunger at mealtimes and lack of food enjoyment. Associated weight loss is part of the physical decline that occurs as cancer worsens. Weight loss can also occur from cachexia, the increased metabolism of energy due to raised inflammatory cytokines, liver metastases and other factors seen in several advanced cancers. Independent of anorexia, although frequently associated (where it is referred to as the cachexia-anorexia syndrome), it accounts for a significant amount of morbidity and deaths in people with cancer. In particular, quality of life for the patient and the family is significantly affected with this syndrome as it causes anxiety and distress. Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population. Cannabinoids are one such group of therapies that have received a large amount of media focus recently. However, there appears to be a lack on rigorous pharmacokinetic data of these complex and varied compounds in the cachexic population. Similarly, there is a lack of pharmacokinetic data in any population group for the non- tetrahydrocannabinol (THC) and cannabidiol (CBD) cannabinoids (often due to the lack of analytical standards for quantification). This review will thus examine the pharmacokinetics of major cannabinoids i.e. THC and CBD in a cancer population. Overall, based on the current literature, evidence for the use of cannabinoids for the treatment of cancer-related cachexia-anorexia syndrome remains equivocal. A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose-concentration and concentration-response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 158 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 19% |
| Student > Bachelor | 24 | 15% |
| Student > Master | 22 | 14% |
| Other | 16 | 10% |
| Student > Ph. D. Student | 10 | 6% |
| Other | 22 | 14% |
| Unknown | 36 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 23% |
| Biochemistry, Genetics and Molecular Biology | 13 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 8% |
| Nursing and Health Professions | 12 | 8% |
| Neuroscience | 8 | 5% |
| Other | 31 | 19% |
| Unknown | 46 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2018.
All research outputs
#13,458,480
of 22,849,304 outputs
Outputs from Clinical Pharmacokinetics
#1,092
of 1,481 outputs
Outputs of similar age
#142,826
of 297,534 outputs
Outputs of similar age from Clinical Pharmacokinetics
#9
of 16 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,481 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,534 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.